BCG-CWS联合IL-2预防浅表性膀胱癌术后复发

目的：探讨介苗细胞壁骨架（BCG－WCS）＋白细胞介素2（IL－2）膀胱灌注预防浅表性膀胱癌术后复发的临床效果。方法56例浅表性膀胱癌局部手术后随机分为两组，每组28例。分别采用BCG－CWS加IL－2和单用丝裂霉素C（MMC）进行膀胱灌注。结果：56例随访12－30个月，平均22．9个月，BCG－WCS＋IL－2组有1例肿瘤复发，MMC组有5例肿瘤复发，两组肿瘤复发率判别有显著性意义（P＜0．05）；MMC灌注组的毒副反应较BCG－WCS＋IL－2组多。结论BCG－CWS联合IL－2预防浅表性膀胱癌术后复发疗效较好，副反应少，临床使用安全可靠。

The clinical use of BCG-CWS and IL-2 for preventing recurrence of superficial bladder cancer

Objective　To study the therapeutic effects of intravesical instillation of cell wall skeleton of bacillus Calmett-Guerin ( BCG-CWS ) and interleukin 2 (IL-2 ) in preventing bladder cancers from recurring after local ablation.Methods　56 patients with superficial bladder cancers were randomized in using BCG-CWS and IL-2 or MMC for preventing bladder cancers from recurring after local ablation.Results　The patients have been followed up for 12～30 months (mean 22.9 months).One patient had tumor recurrence in the group using BCG-CWS and IL-2 and five in the MMC group,the rates of tumor recurrence were 3.6%（1/28）and 18.0%（5/28） respectively, and the difference was statistically significant(P<0.05). There were obviously more side effects in intravesical instillation with MMC than BCG-CWS and IL-2.Conclusions　Intravesical instillation of BCG-CWS and IL-2 is effective in preventing superficial bladder cancer from recurring after local ablation with fewer adverse effects.The ragimen is not only reliable but also safe.